PRPH
ProPhase Labs, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.02
+17.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.2M | 4.3M | 6.8M | 44.4M | 122.6M |
| Cost of Revenue | 2.6M | 3.0M | 6.9M | 28.1M | 52.0M |
| Gross Profit | 517.0K | 1.4M | (150.0K) | 16.2M | 70.7M |
| Operating Expenses | |||||
| R&D Expense | 6.0K | 107.0K | 594.0K | 1.4M | 652.0K |
| SG&A Expense | 13.4M | 19.3M | 37.9M | 34.5M | 46.4M |
| General & Admin Expense | 13.4M | 19.3M | 37.9M | 34.5M | 46.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.9M | — | — | 1.9M | — |
| Total Operating Expenses | 16.3M | 19.4M | 38.5M | 37.9M | 47.1M |
| Cost and Expenses | 18.9M | 22.4M | 45.4M | 66.0M | 99.1M |
| Operating Income (EBIT) | (15.7M) | (18.0M) | (38.6M) | (21.6M) | 23.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | 78.0K | 153.0K |
| Interest Expense | 7.2M | 6.9M | 3.4M | 1.3M | 764.0K |
| Net Interest Income | (7.2M) | (6.9M) | (3.4M) | (1.2M) | (611.0K) |
| Other Non-Op Income/Expense | (6.3M) | (5.3M) | (3.7M) | (785.0K) | (687.0K) |
| Non-Operating Income (excl Interest) | (557.0K) | (1.6M) | 351.0K | (88.0K) | (77.0K) |
| EBT (Pre-Tax Income) | (22.0M) | (23.4M) | (42.3M) | (22.4M) | 22.9M |
| Income Tax Expense | 607.0K | — | 7.2M | (6.0M) | 4.4M |
| Bottom Line | |||||
| Net Income | (22.6M) | (14.7M) | (53.4M) | (16.8M) | 18.5M |
| Earnings from Cont. Ops | (22.6M) | (23.4M) | (49.5M) | (16.4M) | 18.5M |
| Earnings from Discont. Ops | — | 8.6M | (3.8M) | (402.0K) | — |
| Bottom Line Net Income | (22.6M) | (14.7M) | (53.4M) | (16.8M) | 19.1M |
| Per Share | |||||
| Basic EPS | ($3.12) | ($1.74) | ($26.10) | ($9.80) | $11.70 |
| Diluted EPS | ($3.12) | ($1.74) | ($26.10) | ($9.80) | $10.20 |
| Revenue Per Share | $0.23 | $0.51 | $3.55 | $25.79 | $77.40 |
| Shares | |||||
| Basic Shares Outstanding | 14.0M | 8.5M | 1.9M | 1.7M | 1.6M |
| Diluted Shares Outstanding | 14.0M | 8.5M | 1.9M | 1.7M | 1.9M |
| Profitability Metrics | |||||
| EBITDA | (7.1M) | (11.4M) | (32.3M) | (14.8M) | 28.7M |
| D&A | 8.0M | 5.1M | 6.6M | 6.7M | 5.1M |
| EBIT | (15.2M) | (16.5M) | (39.0M) | (21.5M) | 23.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026